Nuclear medicine imaging of lung cancer and esophagus cancer

作者: Gunnar Herlin

DOI:

关键词:

摘要: Background: Somatostatin receptors (SSTRs) occur in cancer tissue, and Tc-depreotide is a labelled somatostatin receptor analogue, binding to SSTRs subtype 2, 3, 5. Purpose: The general aim of the present thesis was study scintigraphy (SSTRS) with diagnosis characterization cancers lung oesophagus. Study I evaluated diagnostic value SSTRS 99 patients suspected cancer. sensitivity detect malignancy 94%, 98%. specificity calculated on two sets data. When all cases are used, 52%. If 12 pneumonias excluded, 77%. II performed 19 histologically proven non-small-cell (NSCLC), where expression SSTR 2 looked for found by immunochemical methods. quantitative evaluation using region-of-interest analysis includes tumour counts/cm, background ratio between counts. positively correlated degree tumour’s differentiation (p < 0.05). uptake cells did not correlate grade or MIB-1, p53 expression. III showed feasibility imaging oesophageal carcinoma Tcdepreotide optimal time intervals imaging. None 13 cancer-free Barrett’s oesophagus this an increased uptake. IV investigated 2A, 2B, 5 28 cancer, detected small amount adenocarcinoma absent squamous cell carcinoma. There no correlation SSTRs, tumour. Conclusion: labeled analogue has very high detecting A negative strongly suggests benign lesion, method useful decision making respect surgery. NSCLC positive presence 2. compared differentiation, p53, cannot be used as prognostic factor feasible, but suitable, either screening primary diagnosis, because method’s modest sensitivity. However, specificity. majority adenocancer have low while most do any SSTRs. © Gunnar Herlin, 2011 ISBN 978-91-7457-403-6

参考文章(93)
Hermann L. Müller, Michael C. Frühwald, Max Scheubeck, Johann Rendl, Monika Warmuth-Metz, Niels Sörensen, Joachim Kühl, Jean C. Reubi, A possible role for somatostatin receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma. Journal of Neuro-oncology. ,vol. 38, pp. 27- 40 ,(1998) , 10.1023/A:1005961302340
Gunnar Myrdal, Mats Lambe, Reinhold Bergström, Anders Ekbom, Gunnar Wagenius, Elisabeth Ståhle, Trends in lung cancer incidence in Sweden with special reference to period and birth cohorts. Cancer Causes & Control. ,vol. 12, pp. 539- 549 ,(2001) , 10.1023/A:1011238525498
M. Hofmann, H. Maecke, A. Börner, E. Weckesser, P. Schöffski, M. Oei, J. Schumacher, M. Henze, A. Heppeler, G. Meyer, W. Knapp, Biokinetics and imaging with the somatostatin receptor PET radioligand 68 Ga-DOTATOC: preliminary data European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 28, pp. 1751- 1757 ,(2001) , 10.1007/S002590100639
Andrew V. Schally, Oncological applications of somatostatin analogues. Cancer Research. ,vol. 48, pp. 6977- 6985 ,(1988)
Jean Claude Reubi, Jean A. Laissue, Beatrice Waser, Jan-Olaf Gebbers, Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Cancer Research. ,vol. 56, pp. 1922- 1931 ,(1996)
Jean-Claude Reubi, Larry Kvols, Somatostatin Receptors in Human Renal Cell Carcinomas Cancer Research. ,vol. 52, pp. 6074- 6078 ,(1992)
J C Reubi, C Moertel, C C Reading, D M Nagorney, L K Kvols, P U Heitz, J W Charboneau, B Waser, Detection of Somatostatin Receptors in Surgical and Percutaneous Needle Biopsy Samples of Carcinoids and Islet Cell Carcinomas Cancer Research. ,vol. 50, pp. 5969- 5977 ,(1990)
R M Apolinario, P van der Valk, J S de Jong, W Deville, J van Ark-Otte, A M Dingemans, J C van Mourik, P E Postmus, H M Pinedo, G Giaccone, Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 15, pp. 2456- 2466 ,(1997) , 10.1200/JCO.1997.15.6.2456
J S Lee, A Yoon, S K Kalapurakal, J Y Ro, J J Lee, N Tu, W N Hittelman, W K Hong, Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. Journal of Clinical Oncology. ,vol. 13, pp. 1893- 1903 ,(1995) , 10.1200/JCO.1995.13.8.1893
C. Waldherr, M. Pless, H.R. Maecke, A. Haldemann, J. Mueller-Brand, The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Annals of Oncology. ,vol. 12, pp. 941- 945 ,(2001) , 10.1023/A:1011160913619